Synthetic HDLs, made with a recombinant form of apoA-IM and phospholipids given in two injections four days apart, are effective in inducing the regression of atherosclerotic plaques, in enhancing reverse cholesterol transport [69], in reducing global inflammation [69, 70], in preventing arterial restenosis, limiting cardiac dysfunction after ischemia/reperfusion injury [18, 19], and even in reversing aortic stenosis [71]. The gene discussed is APOA1; the disease is aortic stenosis.